Unique ID issued by UMIN | UMIN000033511 |
---|---|
Receipt number | R000038212 |
Scientific Title | Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes |
Date of disclosure of the study information | 2018/07/26 |
Last modified on | 2021/02/01 11:37:49 |
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp
Japan |
Type2 diabetes
Endocrinology and Metabolism |
Others
NO
For type2 diabetes patients with insufficient control, to examine the improvement of the quality of life (QOL) and the glycemic effect, as basal insulin was switched to IDegAsp with changing from DPP-4 inhibitor to Liraglutide.
Safety,Efficacy
The change in QOL scores from baseline to 3 months in patients with switched therapy to Liraglutide/IDegAsp.
Difference of change in HbA1c, body weight, units of insulin dose, frequency of hypoglycemia (SMBG), SD and CV % of FPG on SMBG, clinical and laboratory parameters
Observational
20 | years-old | <= |
85 | years-old | > |
Male and Female
1)Patients with type 2 diabetes treated with basal insulin and DPP-4 inhibitor.
2)HbA1c>7.5%
3)Patients who can respond to questionnaire survey.
4)Patients who gave written informed consent.
1)Patients with severe renal dysfunction including patients requiring hemodialysis or peritoneal dialysis(eGFR<30ml/min).
2)pregnant
3)Patients who have severe diabetic ketosis, diabetic coma.
4)Patients with severe infection, severe injury or perioperative state.
60
1st name | Tadashi |
Middle name | |
Last name | Yamakawa |
Yokohama City University Medical Center
Department of Endocrinology and Diabetes
232-0024
4-57 Urafune-cho, Mimami-ku, Yokohama City, 232-0024, Japan
045-261-5656
naibunpi@urahp.yokohama-cu.ac.jp
1st name | Marina |
Middle name | |
Last name | Harada |
Yokohama City University Medical Center
Department of Endocrinology and Diabetes
232-0024
4-57 Urafune-cho, Mimami-ku, Yokohama City, 232-0024, Japan
045-261-5656
onyogora@yokohama-cu.ac.jp
Yokohama City University Medical Center
Department of Endocrinology and Diabetes
none
Self funding
Medical Ethics Committee for Humans
3-9 FukuuraKanazawa-ku, Yokohama City, Japan
0453707627
rinri@yokohama-cu.ac.jp
NO
横浜市立大学附属市民総合医療センター
浦舟金沢内科クリニック
2018 | Year | 07 | Month | 26 | Day |
Unpublished
Terminated
2017 | Year | 08 | Month | 23 | Day |
2017 | Year | 03 | Month | 29 | Day |
2017 | Year | 08 | Month | 24 | Day |
2019 | Year | 12 | Month | 31 | Day |
Observational study based on the questionnaire
Diabetes therapy Related QOL(DTR-QOL)
Problem areas in diabetes survey (PAID)
2018 | Year | 07 | Month | 25 | Day |
2021 | Year | 02 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038212
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |